๐Ÿ“ˆ LEMMING INVESTOR RESEARCH by ๐Ÿ“ˆSmall Company Champion

๐Ÿ“ˆ LEMMING INVESTOR RESEARCH by ๐Ÿ“ˆSmall Company Champion

Share this post

๐Ÿ“ˆ LEMMING INVESTOR RESEARCH by ๐Ÿ“ˆSmall Company Champion
๐Ÿ“ˆ LEMMING INVESTOR RESEARCH by ๐Ÿ“ˆSmall Company Champion
SkinBioTherapeutics PLC

SkinBioTherapeutics PLC

Inflection Points - Turning a Corner with Breakthrough Potential

Alex Langton's avatar
Alex Langton
Apr 17, 2025
โˆ™ Paid
24

Share this post

๐Ÿ“ˆ LEMMING INVESTOR RESEARCH by ๐Ÿ“ˆSmall Company Champion
๐Ÿ“ˆ LEMMING INVESTOR RESEARCH by ๐Ÿ“ˆSmall Company Champion
SkinBioTherapeutics PLC
3
15
Share

By Alex Langton | 17 April 2025

Mike, Elric, and I have a financial interest in SkinBioTherapeutics.

Father, aka the โ€˜old dufferโ€™ was up into the small hours hammering on the keyboard, updating Fresnillio and Journeo, for the Small Company Champion side. Both companies are going great guns. On to SkinBioTherapeutics, so you have to suffer me today. The main focus will be on potential inflection points we deliberately ignored in our article yesterday, because, as you could see, Zenakineโ„ข needed special care and attention.

SkinBioTherapeutics PLC

SkinBioTherapeutics PLC

๐Ÿ Elric Langton and Alex Langton
ยท
Apr 16
Read full story

After a protracted period of uncertainty, SkinBioTherapeutics appears to have decisively recalibrated its trajectory, emerging with renewed vigour and a commercially potent proposition at its core. For investors who tuned into the companyโ€™s latest presentation hosted by IMC, and indeed, we believe HNWI investors and institutions have been provided separate presentations, the message from Dr Surinder 'Dass' Chahal was unequivocal: the future of skincare may well be written in the name Zenakineโ„ข. The standing ovation received at its recent technical launch at in-cosmetics Global in Amsterdam was no mere formality; it marked the arrival of a disruptive ingredient that has set the cosmetics industry abuzz.

Zenakineโ„ข: Neurocosmetics Redefined

Positioned at the vanguard of neuroactive skincare, Zenakineโ„ข is not merely another activeโ€”rather, it signals a paradigm shift. Developed in collaboration with Croda, one of the industryโ€™s most sophisticated operators, the ingredient has shown clinically validated results in mitigating cortisol-induced damage, recalibrating the skin's circadian rhythm, and delivering profound anti-ageing outcomes. These attributes, which straddle both physical rejuvenation and emotional well-being, offer a compelling value proposition to high-end formulators seeking differentiation in an increasingly crowded market.

Crodaโ€™s early commercial mobilisation of Zenakineโ„ข, coupled with its distribution firepower, sets the stage for a swift and broad-based market adoption. It is entirely plausible, given early indicators, that Zenakineโ„ข could be incorporated into formulations from major global cosmetics brands within the next 18 monthsโ€”paving the way for annualised gross profits to enter seven-figure territory by the close of FY2026.

Clarity on Capital: A Stronger Financial Base

This post is for paid subscribers

Already a paid subscriber? Sign in
ยฉ 2025 ๐Ÿ“ˆ ๐Ÿ Small Company Champion - Small Company Media Ltd
Privacy โˆ™ Terms โˆ™ Collection notice
Start writingGet the app
Substack is the home for great culture

Share